ArticleArchives of Razi Institute2024
Cerebral Inhibition of the H3K9 Methylation Could Ameliorate Blood-Brain Barrier Dysfunction and Neural Damage in Vascular Dementia.
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Caffeic acid phenethyl ester alleviates 1,2-dichloroethane-induced toxic cerebral edema: central and peripheral mechanisms.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia encompasses a broad category of brain diseases characterized by various degenerative or vascular components that lead to a long-term and often gradual decline in cognitive abilities, significantly affecting daily functioning. Literature indicates that the G9a/GLP enzyme, through the upregulation of histone 3 lysine 9 dimethylation (H3K9me2), plays a pivotal role in vascular dementia (VD). The increase in H3K9 methylation by G9a/GLP during VD inhibits the expression of neuroprotective proteins and diminishes the expression of proteins crucial for maintaining blood-brain barrier (BBB) integrity. Using a model of permanent common carotid artery (CCA) occlusion, we investigated the effects of a G9a/GLP inhibitor (BIX01294) on VD. Following CCA occlusion, BIX01294 (22.5 µg/kg) was administered intraperitoneally three times a week for one month. We assessed neuronal damage using Nissl staining, BBB permeability via the Evans blue test, and measured brain water content. Western blot analysis was employed to evaluate the hippocampal levels of Bax and Bcl2 proteins. Treatment with BIX01294 enhanced BBB stability (P < 0.05) and subsequently reduced brain edema compared to the VD group (P < 0.05 for both measures). Neuronal injury in the CA1 region of the hippocampus significantly decreased following BIX01294 administration compared to the VD group (P < 0.05). Furthermore, the Bax/Bcl2 ratio markedly decreased in the treatment group (P < 0.0001). In summary, our research demonstrates that inhibiting H3K9 methylation can prevent the progression of vascular dementia by reducing cerebral edema and neuronal apoptosis in the hippocampus following ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.